Screening for hepatitis; Screening for hepatitis done ICD-10-CM Diagnosis Code Z11.59 [convert to ICD-9-CM] Encounter for screening for other viral diseases
ICD-10-CM Diagnosis Code B15.9 [convert to ICD-9-CM] Hepatitis A without hepatic coma Acute hepatitis a; Acute type a viral hepatitis; Hepatitis a; Viral hepatitis, type a; Hepatitis A (acute) (viral) NOS ICD-10-CM Diagnosis Code B18.9 [convert to ICD-9-CM]
Hepatitis D, also known as "delta hepatitis," is a serious liver disease caused by infection with the Hepatitis D virus (HDV). This is an RNA virus structurally unrelated to the Hepatitis A, B, or C viruses. Hepatitis D, which can be acute or chronic, is uncommon in the United States.
Z11.59 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM Z11.59 became effective on October 1, 2020. This is the American ICD-10-CM version of Z11.59 - other international versions of ICD-10 Z11.59 may differ. Z codes represent reasons for encounters.
2022 ICD-10-CM Diagnosis Code Z11. 59: Encounter for screening for other viral diseases.
ICD-10-CM Diagnosis Code B18 B18.
Screening for hepatitis B involves blood tests that measure HBV antigens and antibodies. The test for hepatitis B surface antigen detects the presence of HBV. A positive result means the person is currently infected and can pass the infection to others.
Z22. 51 Carrier of viral hepatitis B - ICD-10-CM Diagnosis Codes.
Unspecified viral hepatitis without hepatic coma B19. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM B19. 9 became effective on October 1, 2021.
A Hepatitis B (HBV) Blood Test Panel includes a Hepatitis B Core Antibody Total (Test #006718), Hepatitis B Surface Antigen (Test #006510), Hepatitis B Surface Antibody (Test #006395). Preparation: No fasting required. Stop biotin consumption at least 72 hours prior to the collection.
The American Association for the Study of Liver Diseases (AASLD) recommends that in men infected with hepatitis B, liver cancer screening should start at age 40 years and in infected women at age 50 years.
CDC recommends that the following people be screened for HBV infection (8,9,10): People born in countries with prevalence of HBV infection ≥2% People born in the United States not vaccinated as infants whose parents were born in regions with high rates of HBV infection (HBsAg prevalence of ≥8%)
The hepatitis virus panel is a series of blood tests used to detect current or past infection by hepatitis A, hepatitis B, or hepatitis C. It can screen blood samples for more than one kind of hepatitis virus at the same time. Antibody and antigen tests can detect each of the different hepatitis viruses.
Chronic viral hepatitis B18-
Assign code 070.1 for a hepatitis A diagnosis or 070.0 for hepatitis A with hepatic coma. 070.32, Chronic hepatitis B without hepatic coma. 070.71, Unspecified viral hepatitis C with hepatic coma.
Who are hepatitis B carriers? Hepatitis B carriers are people who have the hepatitis B virus in their blood, even though they don't feel sick. Between 6% and 10% of those people who've been infected with the virus will become carriers and can infect others without knowing it.
The patient’s primary care physician or practitioner, an eligible Medicare provider, must order the screening within the context of a primary care setting.
For HBV screening in pregnant women (CPT codes 86704, 86706, 87340 and 87341) report Z11.59 Encounter for screening for other viral diseases with one of the following diagnosis codes:
Hepatitis refer to inflammation of the liver that can caused by virus infections that affect the liver. Viral hepatitis is a relatively common disease (25 patients in every 100,000 citizens in the US) caused by a diverse group of hepatotropic agents that lead to liver inflammation and liver cell death.
The CDC has recommendations regarding Hepatitis screening for both hepatitis B and hepatitis C for persons at high risk for infection.
Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.
04/2017 - CMS has determined that effective September 28, 2016, screening for HBV infection will be covered with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA-approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations.
This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.